MENU CLOSE
About Us

Who We Are

Our Social Responsibility

Events

Exhibitions

Activeties

Members

Hospitals

Individuals

Companies

Member Benefits

 
Bio-medical projectsi

State Key Laboratory of Biotherapy

Cooperation

Achievement Exhibition

Scimea Journals

Signal Transduction and Targeted Therapy

News

News Information

 
Home   >  News
19 Jun 2020
392
MedComm | Vitamin intervention for cytokine storm in the patients with coronavirus disease 2019
Scimea

Recently, Jian‐Sheng Kang reported a strategy for protecting patients with COVID-19, based on vitamin intervention for cytokine storm. As the global pandemic is still growing, if the vitamin intervention for cytokine storm could be proved to be applicable and efficient, it would be tremendously helpful and easy to protect the patients with COVID‐19 worldwide from the cytokine storm‐related death.

 



 1598428951(1).png


Two recent clinical summaries of patients with COVID‐19 reported that cytokine storm was associated with the severity and death of patients with COVID‐19. Thus, it was urgent to seek effective prevention and treatments for the cytokine storm in COVID19 patients, especially those under intensive care unit (ICU). Interestingly, the oral administration of sufficient Vc might be sufficient to ameliorate the cytokine storm caused by neutrophils. In addition, 110 nM of vitamin D (Vd) via vitamin D receptor (VDR) could efficiently suppress the cytokine production of Th17 by inducing the expression of C/EBP homologous protein (CHOP). Together, the simultaneous administration of sufficient Vc and Vd might ameliorate the neutrophilrelated cytokine storm in the patients with COVID19, especially those under ICU (Fig. 1).

 

 

图片.png 

Fig. 1 Vitamin Intervention for neutrophil‐related cytokine storm.

 

 

 

Article Access: https://onlinelibrary.wiley.com/doi/10.1002/mco2.7

 

 

                                                                                                                        

Website for MedComm: https://onlinelibrary.wiley.com/journal/26882663

Looking forward to your contributions.


Exchange and Cooperation | Sichuan International Medical Exchange & Promotion Association Visits Thecover.cn for Exchange
Japan Kobe Translational Research Center for Medical Innovation (TRI) China Headquarters Officially Unveiled
MedComm | Intermedin promotes vessel fusion by inducing VE‐cadherin accumulation at potential fusion sites and to achieve a dynamic balance between VE‐cadherin‐complex dissociation/reconstitution
Interview | Man Zhiwei: China’s Advance of New Drug R&D Is Unstoppable
​Professor Masoud Mozafari from Canada Publishes a Paper on MedComm: Opportunities and Challenges of "Zeolite" in Tissue Engineering
Latest Events Journals News Members About Us Home
Contact Us

Address: No. 1103-1105, Building 6, S2, Global Center, High-tech Zone, Chengdu

Email: scimea@163.com 

Tel: (0086-)028-63859818   

Fax: (0086-)028-63859818   

Contact: (0086-)19113901604 (wechat:19113901604)


Follow Us
Copyright © 2009-2019 SCIMEA. All rights reserved 蜀ICP备19011649号-1